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Available online 16 February 2016AbstractPurpose: The criteria for identifying lung cancer patients with metastatic spinal cord compression (MSCC) who may benefit from decom-
pressive surgery remains unclear. This study aims to create a new therapeutic strategy which can guild surgeons to select the individual
treatment for MSCC patients from lung cancer.
Methods: We retrospectively assessed 73 consecutive lung cancer patients who were treated with decompressive surgery for MSCC. Twelve
preoperative characteristics were analyzed for postoperative survival. Characteristics significantly associated with survival in the multivar-
iate analyses were included in a scoring system. The total score for each patient was obtained by adding the scoring points of all significant
characteristics. Postoperative function outcome was also analyzed according to prognostic groups.
Results: In the multivariate analyses, preoperative ambulatory status (P ¼ 0.02), targeted therapy (P ¼ 0.01), number of involved vertebrae
(P < 0.01), visceral metastases (P < 0.01), and time developing motor deficits (P < 0.01) had significant impact on survival and were
included in the scoring system. According to the prognostic scores, which ranged from 15 to 35 points, three prognostic groups were de-
signed: 15e23 points (n ¼ 32), 25e29 points (n ¼ 26), and 31e35 points (n ¼ 15). The corresponding median survival times were 2.6
months (95% CI, 1.5e4.3 months), 7.2 months (95% CI, 6.0e10.8 months) and 13.2 months (95% CI, 8.8e18.7 months), respectively
(P < 0.01), and the corresponding postoperative ambulatory rates were 46.9%, 80.8%, and 93.3%, respectively (P < 0.01).
Conclusion: We present a scoring system for lung cancer patients with MSCC after surgery based on survival and functional outcome. The
scoring system can guild surgeons to select the individual strategy for patients with MSCC from lung cancer.
 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
Keywords: Lung cancer; Individual strategy; Spinal cord compression; Spine metastasis; Surgical decompression and stabilizationSCC, metastatic spinal cord compression; ECOG,
cology group; CI, confidence interval.
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).Introduction
Metastatic spinal cord compression (MSCC) is radio-
graphically defined as an epidural metastatic lesion causing
true displacement of the spinal cord from its normal posi-
tion, which is an essential source of morbidity in patients
with systemic advanced cancer. MSCC can result in paral-
ysis, bowel and bladder disorders with a highly negative
impact on patient’s quality of life.1 Approximately 28%
of patients with lung cancer are estimated to develop
MSCC during their disease course,2 and MSCC secondary
to lung cancer has worse prognosis compared to MSCCess article under the CC BY-NC-ND license (http://creativecommons.org/
729M. Lei et al. / EJSO 42 (2016) 728e734related to other solid tumors.3 Individual strategies are
particularly important for patients with MSCC, especially
for patients with MSCC resulted from lung cancer. Howev-
er, the standard treatment for MSCC remains controversial.
In 2005, a randomized trial (n ¼ 101) showed that decom-
pressive surgery following by radiotherapy was superior to
radiation alone.4 But more recently, Rades et al.5 did not
find any benefit of surgery following by radiotherapy
when compared with radiotherapy alone in a matched
pair analyses (n ¼ 324).
Moreover, the criteria for identifying patients with
MSCC who may benefit from decompressive surgery is still
unclear, let alone especially for identifying lung cancer pa-
tients with MSCC. Recently, only a few studies specifically
addressed surgical treatment of MSCC in lung cancer.6e8
Several scoring systems have been proposed to assess sur-
vival prognosis for spinal metastasis from various primary
tumors.9e15 The most currently used scores are those devel-
oped by Tokuhashi et al.9 and Tomita et al.12 Both recom-
mend that treatment strategy be based on survival
prognosis. However, these scores were developed in retro-
spective studies comprising relatively small number of pa-
tient with lung cancer, making it difficult to draw
conclusions on this specific tumor entity. Each tumor entity
leading to spinal metastasis and consequent MSCC has its
own biological behavior and metastatic patterns, so a score
for each tumor entity is really needed, and only if specific
scores are available for each of these entities can optimal
treatment personalization be realized. Besides, several
studies strongly suggested that some old and commonly-
used scoring systems have underestimated the life expec-
tancy of patients with spinal metastases of lung cancer
due to the increased survival time in recent years.16,17
Furthermore, the choice of survival duration as a unique
criterion in those scoring systems for patient selection can
be challenged because quality of life and functional
outcome are also of utmost importance in the metastatic
background.
Therefore, our present study is designed to develop a
survival score and analyze functional outcome particularly
for patients with MSCC from lung cancer to help select in-
dividual strategy for those patients.
Patients and methodsPatientsSeventy-three patients with lung cancer who were oper-
ated with decompression and spine stabilization for MSCC
were retrospectively analyzed in the study at the Affiliated
Hospital of Academy of Military Medical Sciences, Bei-
jing, between May 2005 and May 2015. The diagnosis of
bone metastasis in lung cancer patients was confirmed his-
tologically, adequate diagnostic imaging including spinal
CT or MRI, as well as bone scan. The data were collected
from patients, their family members, treating surgeons, andpatients’ files. The Medical Research Ethics Board of the
Affiliated Hospital of Academy of Military Medical Sci-
ences approved this retrospective study and required neither
patient approval nor informed consent for review of pa-
tients’ images and medical records. The data were retro-
spective in nature and anonymized by the Medical
Research Ethics Board of the Affiliated Hospital of Acad-
emy of Military Medical Sciences.Survival analysesWe retrospectively analyzed 12 preoperative characteris-
tics for postoperative survival, including age (57 years vs.
>57 years; median age: 57 years), gender (female vs.
male), histology (adenocarcinoma vs. nonadenocarcinoma),
preoperative ambulatory status (ambulatory vs. not ambula-
tory), other bone metastases (no vs. yes), preoperative
chemotherapy (no vs. yes), targeted therapy (no vs. yes),
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status (1e2 vs. 3e4), number of involved vertebrae
(1e2 vs. 3), visceral metastases (no vs. yes), interval
from cancer diagnosis to surgery (80 days vs. >80
days; median time: 80 days), and the time developing motor
deficits before surgery (14 days vs. >14 days; median
time: 14 days).
The postoperative survival was defined as the time be-
tween the date of surgery and death or the latest follow-
up. For the present study, we included all 73 patients
with lung cancer who had decompressive surgery and spine
stabilization due to spinal cord compression. None of the
patients were excluded for any reason. Eight patients
were still alive by the end of the study period, with a
mean follow-up of 7.6 months in those patients. In patients
who had surgery for more than one metastasis, all sites
were included in the analyses. However, only the first sur-
gical procedure was accounted for in the survival analyses.Surgery and functional evaluationThe indication for surgery was neurological deficit due
to MSCC. All patients were operated with decompression
and spine stabilization (Fig. S1, a case report). Local radio-
therapy, systemic chemotherapy, and targeted therapy with
gefitinib were performed after the wound healed, about
3e4 weeks after the surgery. Postoperative functional
outcome was analyzed according to the scoring system.
Neurological function was graded based on Frankel score
preoperatively and 4 weeks postoperatively (Patients with
Frankel D and E have the ability to walk). Ambulatory sta-
tus was defined that a patient could take at least two steps
with each foot unassisted, even if a cane or walker was
needed, which was developed from Patchell et al.4 Time
developing motor deficits defined as the time between dete-
rioration of motor function to disability or surgery. Deteri-
oration of motor function was defined as a change of at
least one Frankel grade.
730 M. Lei et al. / EJSO 42 (2016) 728e734Statistical analysesThe univariate and multivariate analyses of postopera-
tive survival were performed using the KaplaneMeier
method and Cox proportion hazards model, respectively.
The prognostic factors that were significant in the multivar-
iate analyses were included in the scoring system. The
score for each significant prognostic factor was calculated
by dividing the 6-month survival rate (in %) by 10.15 The
total prognostic score for each patient was determined by
adding the scoring points of every significant factor. Neuro-
logical outcome in risk groups was compared with Chi-
square test. A P value of 0.05 or less was considered statis-
tically significant. Statistical analyses were performed us-
ing SAS 9.2 software.
ResultsSurvivalIn the entire cohort of 73 patients, the overall median
survival time was 6.0 months (95% CI, 4.5e7.1 months),
6-month and 12-month survival rates were 49% and 22%,
respectively. At the latest follow-up, eight patients were
still alive, with a mean follow-up of 7.6 months
(1.5e39.0 months).Development of a new scoreIn the univariate analyses, survival was significantly
associated with preoperative ambulatory status (HR, 1.95,
95% CI: 1.17e3.25; P ¼ 0.01), targeted therapy (HR,
2.38, 95% CI: 1.39e4.08; P < 0.01), ECOG performance
status (HR, 2.57, 95% CI: 1.47e4.49; P < 0.01), number
of involved vertebrae (HR, 2.81, 95% CI: 1.62e4.85;
P < 0.01), visceral metastases (HR, 2.55, 95% CI:
1.52e4.28; P < 0.01), and time developing motor deficits
(HR, 3.70, 95% CI: 2.09e6.57; P < 0.01) (Fig. S2, Table
1). According to the multiple Cox proportional hazards
model, five of above six factors, preoperative ambulatory
status (HR, 1.93, 95% CI: 1.12e3.34; P ¼ 0.02), targeted
therapy (HR, 2.13, 95% CI: 1.19e3.82; P ¼ 0.01), number
of involved vertebrae (HR, 2.36, 95% CI: 1.32e4.22;
P < 0.01), visceral metastases (HR, 2.33, 95% CI:
1.31e4.14; P < 0.01), and time developing motor deficits
(HR, 2.38, 95% CI: 1.27e4.46; P < 0.01) maintained sig-
nificant impact on survival and were included in the scoring
system (Table 1). The scoring points for each of the five
significant factors obtained from the 6-month survival rates
were seen in Table 2. The prognostic score for each patient
was calculated by adding the scoring points of the five sig-
nificant characteristics. The addition resulted in prognostic
scores of 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35 points.
The 6-month survival rates, median overall survival time,
and the total number of patients of each prognostic score
were shown in Fig. 1. Taking into account the 6-monthsurvival rates and median overall survival time of the prog-
nostic scores, the following three survival groups were
formed: 15e23 points (group A, n ¼ 32), 25e29 points
(group B, n ¼ 26), and 31e35 points (group C, n ¼ 15,
5 patients were still alive). The corresponding median sur-
vival times were 2.6 months (95% CI, 1.5e4.3 months), 7.2
months (95% CI, 6.0e10.8 months) and 13.2 months (95%
CI, 8.8e18.7 months), 6-month survival rates were 9.9%,
70.0% and almost 100.0%, respectively, and 12-month sur-
vival rates were 0.0%, 22.9%, and 64.3%, respectively
(P < 0.01, Fig. 2).Functional outcomeThe functional outcome was worse in the group of pa-
tient with 15e23 points (group A) when compared with
the other two prognostic groups (Table 3). In detail, only
46.9% (15/32) patients were able to walk (Frankel D/E) 4
weeks after surgery in group A, 80.8% (21/26) patients in
group B, and 93.3% (14/15) patients in group C
(P ¼ 0.0015).
In the entire cohort of 73 patients, 68.5% (50 of 73) pa-
tients were able to walk 4 weeks after decompression, 8 pa-
tients died within 4 weeks after surgery and none of them
achieved ambulatory status. 51.5% (17/33) of nonambula-
tory patients (Frankel B/C) before operation regained the
ability to walk. 82.5% (33/40) of ambulatory patients main-
tained their neurological status, whereas 17.5% (7/44) of
ambulatory patients before surgery lost their ability to
walk for disease progression (4 patients) and postoperative
complication (3 patients).
Discussion
Currently, the most appropriate treatment for MSCC is
still controversial. A phase III trial strongly suggested
that direct decompressive surgery followed postoperative
radiotherapy was superior to treatment with radiotherapy
alone for MSCC in 2005.4 However, Rades et al.5 proposed
the opposite result in 2010, the outcome of radiotherapy
alone was not significantly inferior to those of surgery
plus radiotherapy. Generally speaking, radiation and surgi-
cal decompression are both accepted and effective, and
there appears to be a favorable trend for improved neuro-
logical outcome with surgical decompression and stabiliza-
tion as part of the management.4,18 The choice of
radiotherapy alone or surgery in MSCC depends on accu-
rate patient selection. Selection of the optimal treatment
for the individual patient should take into account patient’s
estimated survival time and functional outcome after thera-
pies.19,20 Patients with very short survival time and poor
functional outcome appear to be best treated with radio-
therapy, or even best supportive care alone, which means
less discomfort for these debilitated and enervated patient.
In contrast, patient with a more favorable survival prog-
nosis and functional outcome may benefit from surgery,
Table 1
Univariate and multivariate analysis of preoperative characteristics for survival in lung cancer patients with MSCC.
Characteristics Patients (n) MOS (m) Simple Cox regression Multiple Cox regression
HR (95% CI) P HR (95% CI) P
Age
57 years 37 7.1 1.55 (0.93e2.57) 0.09 Not included
>57 years 36 4.8
Gender
Female 25 6.3 1.02 (0.61e1.71) 0.95 Not included
Male 48 5.8
Histology
Adenocarcinoma 52 6.0 1.42 (0.80e2.52) 0.24 Not included
Nonadenocarcinoma 21 5.6
Preoperative ambulatory status
Ambulatory 40 6.3 1.95 (1.17e3.25) 0.01 1.93 (1.12e3.34) 0.02
Not Ambulatory 33 4.8
Other bone metastases
No 16 7.9 1.26 (0.70e2.27) 0.44 Not included
Yes 57 4.9
Preoperative chemotherapy
No 44 5.8 1.12 (0.67e1.86) 0.66 Not included
Yes 29 6.4
Targeted therapy
No 47 4.5 2.38 (1.39e4.08) <0.01 2.13 (1.19e3.82) 0.01
Yes 26 10.8
ECOG performance status
1e2 48 7.9 2.57 (1.47e4.49) <0.01 Not included
3e4 25 4.5
Number of involved vertebrae
1e2 38 7.9 2.81 (1.62e4.85) <0.01 2.36 (1.32e4.22) <0.01
3 35 4.3
Visceral metastases
No 37 8.8 2.55 (1.52e4.28) <0.01 2.33 (1.31e4.14) <0.01
Yes 36 3.4
Interval from cancer diagnosis to surgery
80 days 37 6.7 1.11 (0.67e1.84) 0.68 Not included
>80 days 36 5.2
Time developing motor deficits
14 days 37 3.8 3.70 (2.09e6.57) <0.01 2.38 (1.27e4.46) <0.01
>14 days 36 10.7
Abbreviations: MSCC, Metastatic spinal cord compression; MOS, median overall survival; m, months; HR, hazard ratio; CI, confidence interval; ECOG,
Eastern Cooperative Oncology Group.
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of individual strategy can be estimated with the help of sig-
nificant prognostic factors and scoring systems.Prognostic factorsPreviously, in a retrospective study, we found that post-
operative survival was significantly associated with type of
primary tumor, preoperative ambulatory status, visceral
metastasis, and targeted therapy. Metastatic location, preop-
erative ambulatory status, and time developing motor
deficit had significant impact on postoperative functional
outcome.21 However, those significant factors were not
particularly for patients with MSCC resulted from lung
cancer. Several other prognostic factors have been identi-
fied to have statistically significant associations with sur-
vival. Better postoperative ambulatory status,
improvement in neurologic status after surgery, andpostoperative radiotherapy were significant associated
with longer survival which have been shown in some
studies.6,7 However, those significant factors were in post-
operative level, making it nonsense to determine whether
surgical treatment is appropriate for patients before surgery.
In the present study, we analyzed twelve preoperative
characteristics. Preoperative ambulatory status, targeted
therapy, ECOG performance status, number of involved
vertebrae, visceral metastases, and time developing motor
deficit had significant impact on survival in univariate ana-
lyses. According to the multiple Cox proportional hazards
model, five of above six significant factors, preoperative
ambulatory status, targeted therapy, number of involved
vertebrae, visceral metastases, and time developing motor
deficits, maintained significant impact on survival, which
was in accordance with other studies.2,3,6,10,21 ECOG per-
formance status was significant associated with survival
in univariate analyses, which was in line with Tokuhashi
Figure 2. A new score for lung cancer patient with metastatic spinal cord
compression: survival curves for the three prognostic groups (P < 0.01,
log-rank test).
Table 2
Six-month survival rates and corresponding scores.




Ambulatory 40 56 6
Not Ambulatory 33 42 4
Targeted therapy
No 47 32 3
Yes 26 73 7
Number of involved vertebrae
1e2 38 69 7
3 35 30 3
Visceral metastases
No 37 77 8
Yes 36 23 2
Time developing motor deficits
14 days 37 26 3
>14 days 36 73 7
Prognostic groups Total points
Group A 32 10 15e23
Group B 26 70 25e29
Group C 15 100 31e35
732 M. Lei et al. / EJSO 42 (2016) 728e734et al.,9,11 while it was excluded by the Cox proportional
hazards model. So ECOG performance status was not
included in the scoring system. Postoperative ambulatory
status was strongly related to preoperative ambulatory sta-
tus,21,22 which was included in our scoring system.Scoring systemsVarious scoring systems have been proposed for patient
with spinal metastasis on the basis of retrospective data
from relatively small number of lung cancer patients
treated with surgery or radiotherapy alone. In 1990, Toku-
hashi et al.9 presented a score which is mostly used based
on the data of 64 patients with a metastatic spine tumor
who underwent spinal surgery, and only 6 patients hadFigure 1. The 6-month survival rates (%), the total number of palung cancer (More details were seen in Supplementary
table). In 1995, Sioutos et al.10 developed a score that
comprised 109 patients, including 45 lung cancer patients.
Ten years later, Tokuhashi has revised their score in a series
of 246 patient, and rarely 26 patients with lung cancer.
Notably, 33.3% of participants were not treated with sur-
gery in Tokuhashi’s study.11 The revised Tokuhashi was
found to be very useful to predict survival for patients
with spinal metastases from breast cancer alone23 or solid
cancers.24,25 Unfortunately, the revised Tokuhashi score
which seems to be a suboptimal tool for the prediction of
individual prognosis in the group of lung cancer patients
has been shown in the study of Hessler et al.16 in 2011.
In their study, 67 patients with spinal metastasis from
lung cancer, all of them underwent surgical treatment,
and Hessler et al.16 concluded that the Tokuhashi scoring
system underestimated the life expectancy of patients
with lung cancer due to the increased survival time for
this patient group. In 2013, Morgen et al.17 also found a sta-
tistically significant increase in survival over the years fortients, and the median overall survival time of each score.
Table 3
Neurological recovery of the patient in the three prognostic groups 4 weeks
after surgery. The P-value was obtained from the Chi-square test.




A 15e23 32 15 17 0.0015
B 25e29 26 21 5
C 31e35 15 14 1
733M. Lei et al. / EJSO 42 (2016) 728e734lung cancer patients with MSCC. For patients with lung
cancer who underwent surgery for MSCC, survival
increased from 9% in year 2005 up to 30% in year 2010.
More recent study has reported that only 8.6% patients
actually followed the survivorship pattern as predicted by
Tokuhashi score in a series of 151 patients with spine me-
tastases from primary lung cancer.26 Therefore, with the
increasing survival time of patients with lung cancer during
recent years, the accuracy of the Tokuhashi score was
decreasing over time.27e29 Furthermore, these scores
were designed for patients with spinal metastasis in gen-
eral, not particularly for patients with motor impairment
due to MSCC. Rades et al.15 developed and validated a
scoring system for survival of patients (n ¼ 356, all patients
with lung cancer) with MSCC from non-small cell lung
cancer who had been treated with radiotherapy alone. Apart
from the Rades score, above scoring systems included rela-
tively small number of patients with spinal metastasis from
various primary tumors. In fact, participants in Rades score
were received radiotherapy alone, and the functional
outcome was not considered either. Moreover, patients
had prior surgery to the involved parts of the spinal cord
were excluded in their study.
In our study, a score was developed based on the data
derived from 73 patients with lung cancer who underwent
decompressive surgery and spine stabilization for MSCC.
The indication for surgery was neurological deficits due
to MSCC. The patient’s individual situation, therefore,
was taken more into account in the present scoring system.
Patients with scores of 15e23 points, who survived less
than 3 months in median time and had the worst functional
outcome after surgery compared with other two prognostic
groups, appeared to be best treated with radiotherapy or
best supportive care alone. Patients with scores of 25e29
points should be surgical candidates, because survival prog-
nosis and functional outcome are favorable after surgery.
Patients with scores of 31e35 survived more than 1 year
in median time, and 93.3% patients were ambulatory after
surgery. More radical surgery, such as widely excision of
vertebra metastasis, could be considered in order to realize
better control of local disease and prevent the occurrence of
local disease. Functional outcome was acceptable in the
entire cohort of 73 patients, 68.5% (50 of 73) patients
were able to walk 4 weeks after surgery; 51.5% (17/33)
of nonambulatory patients before operation regained theability to walk. 74e84% patients were able to walk after
surgery4,6 and 22e68% of nonambulatory patients became
ambulatory again in other studies.6,8,30,31
However, our score was based on retrospective data, the
statistical analyses not included a relatively larger number
of patients, and data on systemic treatment following treat-
ment was not available in most patients. Moreover, patients
with asymptomatic MSCC were not included in our study,
so this scoring system might not be suitable for those pa-
tients, and the duration from symptoms to surgery may be
a confounding factor that could bias survival outcome
and surgical results. Therefore, despite good predictive
value in our scoring system, the score still warrants a pro-
spective study to be confirmed.
Conclusion
We present a new score for predicting survival and
functional outcome of patients with lung cancer after de-
compressive surgery. The scoring system can help select
the individual strategy for patients with MSCC from
lung cancer. Patients with scores of 15e23 points have
short survival time and poor functional outcome after sur-
gery. Radiotherapy or best supportive care alone may be
considered in most patients of this group. Patients with
scores of 25e29 points should be surgical candidates,
because survival prognosis and functional outcome are
acceptable after surgery. Patients with scores of 31e35,
who have the most favorable survival prognosis and func-
tional outcome, can be treated with more radical surgery
in order to realize better control of local disease and pre-
vent the occurrence of local disease. Still, a prospective
study is needed.
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